Pipeline + Disease Areas | Aldeyra Therapeutics Inc.

Aldeyra is dedicated to improving the lives of patients suffering from immune-mediated ocular and systemic diseases. We are advancing a broad pipeline of product candidates diversified by chemical composition, mechanism of action, and clinical indication.

Our clinical pipeline encompasses three distinct biological mechanisms of action: Reactive Aldehyde Species (RASP) inhibition, Dihydrofolate Reductase (DHFR) inhibition, and Chaperome (CHP) inhibition. The immunological activity of our product candidates may potentially lead to diminished levels of pathological inflammation via the down-regulation of immune cell activation or proliferation.

Ocular Diseases

Compound	Mechanism	Preclinical	Phase 1	Phase 2	Phase 3	Registration	Next Anticipated Milestone
Ocular Disease
Reproxalap Disease Area: Dry Eye Disease Mechanism: RASP Next Anticipated Milestone: Phase 3 – Part 1 completion Q4 2019	RASP	Preclinical	Phase 1	Phase 2	Phase 3	Registration	Phase 3 – Part 1 completion Q4 2019
Reproxalap Disease Area: Allergic Conjunctivitis Mechanism: RASP	RASP	Preclinical	Phase 1	Phase 2	Phase 3	Registration
ADX-2191 Disease Area: Proliferative Vitreoretinopathy Mechanism: DHFR Next Anticipated Milestone: Phase 3 – Part 1 initiation Q4 2019	DHFR	Preclinical	Phase 1	Phase 2	Phase 3	Registration	Phase 3 – Part 1 initiation Q4 2019
ADX-103/10X Disease Area: Retinal Disease Mechanism: RASP Next Anticipated Milestone: Phase 1/2 initiation 2020	RASP	Preclinical	Phase 1	Phase 2	Phase 3	Registration	Phase 1/2 initiation 2020
Undisclosed Disease Area: Ocular Inflammation Research Collaboration: Undisclosed		Preclinical Research Collaboration: Undisclosed	Phase 1	Phase 2	Phase 3	Registration

Learn More about our ocular disease clinical pipeline

Systemic Diseases

Compound	Mechanism	Preclinical	Phase 1	Phase 2	Phase 3	Registration	Next Anticipated Milestone
Systemic Diseases
Reproxalap Disease Area: Sjögren-Larsson Syndrome Mechanism: RASP	RASP	Preclinical	Phase 1	Phase 2	Phase 3	Registration
ADX-1612 Disease Area: Post-Transplant Lymphoproliferative Disorder Mechanism: CHP Next Anticipated Milestone: Phase 2 initiation H2 2019	CHP	Preclinical	Phase 1	Phase 2	Phase 3	Registration	Phase 2 initiation H2 2019
ADX-1612 Disease Area: Mesothelioma Mechanism: CHP Research Collaboration: Investigator-Sponsored Trial	CHP	Preclinical Research Collaboration: Investigator-Sponsored Trial	Phase 1	Phase 2	Phase 3	Registration
ADX-1612 Disease Area: Ovarian Cancer Mechanism: CHP Research Collaboration: Investigator-Sponsored Trial	CHP	Preclinical Research Collaboration: Investigator-Sponsored Trial	Phase 1	Phase 2	Phase 3	Registration
ADX-629 Disease Area: Autoimmune Disease / Metabolic Disease Mechanism: RASP Next Anticipated Milestone: Phase 1 initiation H2 2019	RASP	Preclinical	Phase 1	Phase 2	Phase 3	Registration	Phase 1 initiation H2 2019
ADX-1615 Disease Area: Autoimmune Disease / Cancer Mechanism: CHP	CHP	Preclinical	Phase 1	Phase 2	Phase 3	Registration
Undisclosed Disease Area: Systemic Inflammatory Disease Mechanism: RASP Research Collaboration: Janssen \| Pharmaceutical Companies of Johnson & Johnson	RASP	Preclinical Research Collaboration: Janssen \| Pharmaceutical Companies of Johnson & Johnson	Phase 1	Phase 2	Phase 3	Registration

Learn More about our systemic disease clinical pipeline